window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 28, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

CRISPR

  • Cell & Gene Therapy,Clinical Trials,Drug Development,FDA,Genetic Diseases,Orphan drugs,Precision medicine,Rare Diseases,Regulatory Affairs

    Intellia reports first positive Phase 3 in vivo CRISPR data in hereditary angioedema

    Intellia Therapeutics has reported positive Phase 3 results for lonvoguran [...]

    April 27, 2026
  • Biotech,Cell & Gene Therapy,Drug Development,Events and Conferences

    ELRIG announces keynotes for inaugural Cell and Gene Therapy 2026 conference

    ELRIG has unveiled the keynote speakers for its inaugural Cell [...]

    January 26, 2026
  • Biotech,Genomics and sequencing,Partnerships & Funding,Rare Diseases,Research & Development

    Chiesi and Arbor partner on rare disease gene editing programmes targeting PH1 and other liver disorders

    Chiesi Group has entered into an exclusive global partnership with [...]

    October 7, 2025
  • European biotech,Genomics and sequencing,Medical devices,Partnerships & Funding,Pharmaceuticals and therapeutics,Precision medicine,Research & Development,Technology and platforms

    Lithuania sets stage for Life Sciences Baltics with multi-billion-euro investments and AI innovation

    Lithuania’s life sciences sector is preparing to showcase its rapid [...]

    September 15, 2025
  • Biologics & Biosimilars,Cell & Gene Therapy,Oncology

    Broken String renews NIST gene editing safety push with INDUCE-seq technology

    Broken String Biosciences has reaffirmed its commitment to supporting the [...]

    August 5, 2025
  • Cell & Gene Therapy,Partnerships & Funding,Technology and platforms

    Broken String and BioLizard partner on AI tool to improve gene editing safety

    Eurostars-3 grant supports development of SafeGuide to reduce time and [...]

    July 14, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy

    MaxCyte and Ori Biotech integrate platforms to improve cell therapy manufacturing

    CD19 CAR CRISPR T cell workflow used to demonstrate shortened [...]

    June 12, 2025
  • Cell & Gene Therapy,Clinical Trials,Patient Centricity,Regulatory Affairs

    Digital shift aims to fix long-term gaps in cell and gene therapy trials

    Medable unveils a patient-first remote model to support 15-year safety [...]

    May 30, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ISS National Lab research advances DNA-inspired cancer nanomaterials for chemotherapy and immunotherapy development
    Categories: Drug Delivery & Formulation, Drug Development, Oncology, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top